Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocugen (OCGN) Research & Development (2016 - 2025)

Ocugen's Research & Development history spans 12 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Research & Development rose 28.7% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $39.7 million, up 23.73%, while the annual FY2025 figure was $39.8 million, 23.73% up from the prior year.
  • Research & Development reached $10.7 million in Q4 2025 per OCGN's latest filing, down from $11.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $18.9 million in Q2 2021 to a low of $2.9 million in Q1 2021.
  • Average Research & Development over 5 years is $10.1 million, with a median of $9.1 million recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 1056.63% in 2021, then plummeted 60.71% in 2023.
  • A 5-year view of Research & Development shows it stood at $7.1 million in 2021, then skyrocketed by 142.57% to $17.2 million in 2022, then crashed by 54.84% to $7.8 million in 2023, then rose by 6.57% to $8.3 million in 2024, then grew by 28.7% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for OCGN's Research & Development are $10.7 million (Q4 2025), $11.1 million (Q3 2025), and $8.4 million (Q2 2025).